Kilkari and mMitra: How Google DeepMind is helping improve maternal health
, a Mumbai-based non-profit focused on
maternal health
, is leveraging AI with pro bono support from
Google DeepMind
to enhance its outreach programs,
Kilkari
and
mMitra
, and is said to be yielding promising results in improving maternal and child health across India.
Kilkari, the world's largest mobile-based maternal health program, partners with India's Ministry of Health to deliver weekly audio messages on pregnancy, childbirth, and childcare to over 60 million women across 27 states. These free calls, starting in the second trimester and continuing until a year post-delivery, aim to reduce healthcare lapses. However, a 23% drop-off rate prompted ARMMAN to collaborate with Google DeepMind to develop an AI model that predicts optimal call times by analyzing anonymized individual and group call behaviors. A pilot in Odisha with 17,500 participants showed a 12% increase in call pickup rates for certain time slots, enhancing the delivery of critical health information.
Similarly, ARMMAN's mMitra program, serving 350,000 women in Maharashtra, used AI to identify participants at risk of disengaging. By prioritizing them for personalized outreach, including in-person support, the program retained 30% of high-risk participants. A health impact assessment revealed significant improvements: women prioritized by the AI were 22% more likely to take iron supplements, 28% more likely to take calcium, and 9% better at tracking their babies' birth weights.
These programs also foster social change, empowering women to advocate for better healthcare and rights for their daughters. ARMMAN's AI-driven approach, replacing assumptions with data-driven insights, demonstrates technology's potential to address global health challenges. With plans for nationwide expansion and open-sourced models, ARMMAN aims to inspire similar innovations worldwide, proving AI's role as an accelerant for progress in maternal health.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
Consumer court in Ernakulam orders ‘IVF clinic' to pay Rs 2.66L for misleading couple
Kochi: The Ernakulam District Consumer Disputes Redressal Commission has ordered a Kochi-based clinic to pay Rs 2.66 lakh to a couple who were misled by false promises of guaranteed success in IVF treatment. The complaint was filed under Section 12 of the Consumer Protection Act, 1986. The couple, married since 2002 and struggling with infertility, had attended a medical camp organized by the opposite party, M/s Broun Hall International India Pvt Ltd, at a hospital in Vadakara. There, Praveen Nair and Praveen Pillai—misrepresenting themselves as infertility specialists—promised a 100% success rate in IVF and urged immediate enrollment, citing high demand. The commission stated that, according to the complainant, an initial advance of Rs 1,000 was collected at the camp, followed by Rs 2.4 lakh once the couple signed up for treatment. However, after the payment was made, the clinic backtracked on its guarantees and demanded an additional Rs 40,000 for further tests. The couple complied, but later realised the treatment was a sham and that the clinic was more of a marketing outfit than a genuine medical provider. When the promised treatment was not delivered and the refund denied, the couple approached the consumer court. The commission bench—comprising DB Binu, V Ramachandran, and TN Srividya—ruled that the promised service was neither provided nor its 100% success guarantee fulfilled, resulting in financial loss and mental distress for the complainant. They stressed the need for strong intervention to protect consumers from such exploitative practices in the healthcare sector. The court ordered the opposing party to return the Rs 2.41 lakh paid by the complainant and an additional Rs 25,000 for court costs and compensation, to be paid within 30 days.
Time of India
2 hours ago
- Time of India
Google DeepMind is ready to start human trials of AI-designed drugs; company exec says, ‘We're getting very close'
Google DeepMind 's drug discovery arm, Isomorphic Labs, is 'ready" to begin human trials of its AI-designed drugs . In an interview with Fortune, Colin Murdoch , President of Isomorphic Labs and Google DeepMind's Chief Business Officer, said that the company is 'getting very close' to starting human trials of these drugs. Tired of too many ads? go ad free now This development signifies a potential step for Isomorphic Labs after years of work on its AI-assisted drug designing. Isomorphic Labs was established as a separate entity from DeepMind in 2021. Its foundation stems from AlphaFold , a notable AI system developed by DeepMind, recognised for its ability to predict protein structures with considerable accuracy. What Google DeepMind exec said about starting human trials for AI-designed drugs During an interview with Fortune in Paris, Murdoch said: 'There are people sitting in our office in King's Cross, London, working, and collaborating with AI to design drugs for cancer. That's happening right now.' 'The next big milestone is actually going out to clinical trials, starting to put these things into human beings. We're staffing up now. We're getting very close,' he added. Isomorphic Labs, the company that spun out from DeepMind in 2021, originated from AlphaFold, an AI system known for accurately predicting protein structures. Over time, AlphaFold evolved to model interactions between proteins and molecules like DNA and drugs, significantly advancing its utility in drug discovery and accelerating the development of new medicines. Talking about AlphaFold, Murdoch highlighted: 'This was the inspiration for Isomorphic Labs. It really demonstrates that we could do something very foundational in AI that could help unlock drug discovery.' In 2024, Isomorphic Labs partnered with Novartis and Eli Lilly after releasing AlphaFold 3. By April 2025, it had raised $600 million in its first external funding round led by Thrive Capital. These moves support its goal of creating a 'world-class drug design engine' that combines AI and pharma expertise to develop medicines more efficiently. Tired of too many ads? go ad free now Alongside supporting existing drug programs, the company is also developing its candidates in fields like oncology and immunology for future licensing. 'We identify an unmet need, and we start our own drug design programs. We develop those, put them into human clinical trials… we haven't got that yet, but we're making good progress,' Murdoch explained. Currently, pharma companies invest millions in drug development, often with only a 10% success rate in trials. Murdoch aims to use AlphaFold's technology to significantly boost these odds, ideally reaching a point where researchers can be fully confident in a drug's effectiveness before human trials begin. 'We're trying to do all these things: speed them up, reduce the cost, but also really improve the chance that we can be successful. 'One day we hope to be able to say — well, here's a disease, and then click a button and out pops the design for a drug to address that disease. All powered by these amazing AI tools,' Murdoch continued.
The Print
6 hours ago
- The Print
It's official: New object zipping through our solar system is the 3rd known interstellar visitor
Astronomers are gearing up to observe it across different wavelengths to learn about its composition, shape, and origin. Findings could offer insights into planetary formation in other star systems. With advanced telescopes like the Vera C. Rubin Observatory in Chile, scientists said that more such interstellar visitors may soon follow. Its open, hyperbolic path confirms its origin beyond our Sun's gravitational grip. Currently, it is just inside Jupiter's orbit and will pass through the inner solar system in October, providing us a brief but exciting window for study. Signs of a tail visible in it suggest it's behaving like a comet, venting gas and dust as it heats up. New Delhi: Astronomers have spotted a rare celestial visitor: 3I/ATLAS, the third confirmed object from outside our solar system. Discovered on July 1 by a telescope in Chile that's part of NASA's ATLAS project, this object is moving at a record 68 km per second, which is faster than any interstellar body seen before. The discovery was described in a circular by the France-based International Astronomical Union on 2 July. New gene therapy holds promise for the hearing impaired Gene therapy is showing real promise for people with congenital deafness, according to a new international study involving Sweden's Karolinska Institute. In a peer-reviewed paper published on 2 July in Nature Medicine Journal, researchers described how they treated 10 patients, aged 1 to 24, in five different hospitals, who had severe hearing loss caused by mutations in the OTOF gene. This gene affects a protein called otoferlin, which is needed to send sound signals from the ear to the brain. The researchers injected a healthy copy of the gene directly into the inner ear. The results were remarkable with most patients regaining some hearing within a month, and all showed significant improvement after six months. The best responses came from children aged 5 to 8. One seven-year-old even began holding conversations within four months. The treatment was also deemed to be safe, with no serious side effects reported in the first 12 months. Researchers are now looking to expand this approach to treat other genetic causes of deafness, using the same gene therapy method. Also Read: That morning brew could be doing more than just jumpstarting your day—helping your cells age gracefully Forest collapse some 252 million years ago A new study has revealed that the worst extinction event on the Earth, 252 million years ago, led to the collapse of tropical forests, whose effects were felt for millions of years after. During what is known as the Permian-Triassic 'Great Dying' event, there was a lot of global warming caused by volcanic activity in Siberia. This global warming was seen as the main reason why most of the living beings died off. But scientists were confused about why the Earth's temperature remained so high even millions of years after the eruptions. Now, researchers from the University of Leeds and the China University of Geosciences in a new peer-reviewed study published 2 July in Nature Communications Journal suggest that the destruction of tropical forests due to the extinction event drastically slowed down carbon sequestration—the process by which plants trap carbon dioxide. Without forests, CO₂ built up and stayed in the atmosphere, keeping the planet hot. They studied ancient fossils and rocks to reconstruct changes in plant life and climate. Their data matched simulations showing how forest loss could explain the prolonged warming. The findings, according to the study, serve as a stark warning: if today's tropical forests collapse due to climate change, we might trigger a similar long-term climate crisis. The first ever complete human genome sequenced from Egypt In a new breakthrough, Italian and British scientists have sequenced the first complete human genome from ancient Egypt, using DNA extracted from a 4,500 to 4,800-year-old skeleton. The study was published in Nature Journal on 2 July. The man whose genome was sequenced lived during the era of the first pyramids and was buried in a hillside tomb in southern Egypt. Genetic analysis shows his ancestry was about 80 percent North African and 20 percent West Asian, which shows the first ever DNA-based evidence of human movement between Egypt and Mesopotamia. The remains reveal signs of hard physical labour, possibly as a potter, though the elaborate burial suggests a higher social status. Extracting ancient DNA from Egypt has long been a challenge due to heat-related degradation of the samples, but new techniques have made this feat possible. This individual's genome opens a new window into Egypt's early history and human migration. Researchers hope future collaborations with Egyptian institutions will expand understanding of ancestry and movement in the ancient world. (Edited by Tony Rai) Also Read: Where no humanoid has gone before: Italian scientists develop world's first flying robot
